1. Effect of a Natural Supplement Containing Curcuma Longa, Guggul, and Chlorogenic Acid in Patients With Metabolic Syndrome.
- Author
-
Patti AM, Al-Rasadi K, Katsiki N, Banerjee Y, Nikolic D, Vanella L, Giglio RV, Giannone VA, Montalto G, and Rizzo M
- Subjects
- Aged, Biomarkers blood, Blood Glucose drug effects, Blood Glucose metabolism, Chlorogenic Acid adverse effects, Cholesterol blood, Commiphora, Female, Humans, Inulin adverse effects, Italy, Male, Metabolic Syndrome blood, Metabolic Syndrome diagnosis, Metabolic Syndrome physiopathology, Middle Aged, Oxidative Stress drug effects, Phytotherapy, Pilot Projects, Plant Extracts adverse effects, Plant Gums adverse effects, Plants, Medicinal, Silymarin adverse effects, Time Factors, Treatment Outcome, Weight Loss drug effects, Chlorogenic Acid therapeutic use, Curcuma, Dietary Supplements adverse effects, Inulin therapeutic use, Metabolic Syndrome drug therapy, Plant Extracts therapeutic use, Plant Gums therapeutic use, Silymarin therapeutic use
- Abstract
The impact of a natural supplement (Kepar; Rikrea, Italy), containing several plant extracts such as curcuma longa, silymarin, guggul, chlorogenic acid, and inulin, was evaluated in 78 patients with metabolic syndrome (MetS; 45 men; age: 62 ± 9 years). Kepar at a dose of 2 pills/d was given for 4 months as add-on therapy to the ongoing treatment, maintained at fixed doses for the entire study. Anthropometric variables, plasma lipids, glucose parameters, and oxidative stress were measured at baseline and after 4 months. We found significant reductions in body weight (from 81.1 ± 13.5 to 79.4 ± 12.5 kg, P < .0001), body mass index (from 29.6 [23.7] to 29.3 [21.9] kg/m(2), P = .001), and waist circumference (from 105 ± 11 to 102 ± 10 cm, P = .0004) as well as in fasting glucose (from 6.5 [11.7] to 6.4 [7.6] mmol/L, P = .014) and total cholesterol (from 4.8 ± 1.4 to 4.5 ± 1.0 mmol/L, P = .03). No significant changes were found in the other appraised parameters, including oxidative stress. In conclusion, after few months of treatment Kepar seems to exert beneficial effects in patients with MetS. Larger studies with a longer follow-up period are needed to confirm these preliminary findings., (© The Author(s) 2015.)
- Published
- 2015
- Full Text
- View/download PDF